Keith Skubitz, M.D.

Dr. Skubitz is a Professor of Medicine, Division of Hematology, Oncology, and Transplantation. He has led the medical oncology arm of the Bone and Soft Tissue Tumor program at the University since 1988.

He received his MD from the Johns Hopkins University School of Medicine. He received his internal medicine training at the University of Minnesota. He completed two fellowships, one in Clinical Pharmacology at Johns Hopkins, and one in Medical Oncology at the University of Minnesota.

Dr. Skubitz cares for patients with a variety of malignancies and related diseases. His research primarily involves drug development and clinical trials, including the use of genomics to identify new drug targets and predict disease outcome.

Selected Publications

Skubitz, K.M.  Neutrophilic Leukocytes, in Wintrobe's Clinical Hematology, Tenth Edition, ed Lee, G.R., Foerster, J., Greer, J., Lukens, J., Rodgers, G., and Paraskevas, F., Williams and Wilkins, Baltimore, p 300-350, 1998.

Skubitz, K.M.  Qualitative Disorders of Leukocytes, in Wintrobe's Clinical Hematology,  Tenth Edition, ed Lee, G.R., Foerster, J. , Greer, J., Lukens, J., Rodgers, G., and Paraskevas, F., Williams and Wilkins, Baltimore, p 1889-1907, 1998.

 Skubitz KM, Campbell KD, Ahmed K, et al.  CD66 family members are associated with tyrosine kinase activity in human neutrophils.  J Immunol 1995; 155:5382-5390.

Skubitz KM, Campbell KD, Skubitz APN.  Cd66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils.  J Leuk Biol 1996; 60:106-117.

Skubitz KM, Campbell KD, Iida J, Skubitz APN.  CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils.  J. Immunol 1996;157: 3617-3626.

Skubitz KM.  A  phase I study of ambulatory continuous infusion Paclitaxel.  Anti-Cancer Drugs 1997; 8:823-828.

Skubitz KM, Skubitz APN.  Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil™).  Anti Cancer Drugs 1998; 9:45-50.

Anderson PM, Schroeder G, Skubitz KM.  Oral glutamine reduces duration and severity of stomatitis after cytotoxic cancer chemotherapy.  Cancer 1998; 83:1433-1439.

Skubitz KM, Campbell KD, Skubitz, APN.  CD63 associates with CD11/CD18 in large  detergent-resistant complexes after translocation to the cell surface in human neutrophils.  FEBS Lett 2000; 469:  52-62.

Skubitz KM, Campbell KD, Skubitz APN.  Synthetic peptides of CD66a neutrophil adhesion to endothelial cells.  J Immunol 2000; 164:4257-4264.

Skubitz KM, Anderson PM.  Inhalational IL-2 liposomes for pulmonay metastases:  A phase I clinical trial.  Anti-Cancer Drugs 2000; 11:555-563.

Skubitz KM, Campbell KD, Skubitz APN.  Synthetic peptides from the N-domains of CEACAMs activate neutrophils.  J Peptide Res 2001; 58:5-5-526.

Skubitz KM.  Phase II trial of pegylated liposomal doxorubicin (DoxilTM) in renal cell cancer.  Invest New Drugs 2002; 20:101-104.

Skubitz KM.  Phase II trial of pegylated liposomal doxorubicin in mesothelioma.  Cancer Invest 2002; 20:693-699.

Skubitz KM, Skubitz APN.  Differential gene expression in renal cell carcinoma.  J  Lab Clin Med 2002; 140:52-64.

Casey RC, Oegema TR Jr, Skubitz KM, Pambuccian SE, Grindle SM, Skubitz AP.  Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells.  Clin Exp Metastasis 2003; 20:143-152.

Cho JY, Skubitz KM, Katz DR, Chain BM.  CD98-dependent homotypic aggregation is associated with translocation of protein kinase Cdelta and activation of mitogen-activated protein kinases.  Exp Cell Res 2003; 286:1-11.

Skubitz KM.  Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.  Cancer Invest 2003; 21:167-176.

Skubitz KM, Skubitz AP.  Differential gene expression in uterine leiomyoma.  J Lab Clin Med 2003; 141:297-308.

Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Skubitz KM, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortari A, Kuroki DW, Wagner JE, Kersey JH.  Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeld anti-CD45 antibody in vitro and in vivo in nude mice.  Cancer Biother Radiopharm 2003; 18:133-145.

Casey RC, Koch KA, Oegema TR Jr, Skubitz KM, Pambuccian SE, Grindle SM, Skubitz AP.  Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers.  Clin Exp Metastasis 2003; 20:343-356.

Skubitz KM, Skubitz AP.  Differential gene expression in leiomyosarcoma.  Cancer 2003; 98:1029-1038.

Skubitz KM, Skubitz AP.  Gene expression in aggressive fibromatosis.  J Lab Clin Med 2004; 143: 89-98.

Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr, Skubitz AP.  Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.  Gynecol Oncol 2004; 93:170-181.

Skubitz KM, Skubitz AP.  Role of gene expression arrays in sarcomas.  Curr Oncol Rep 2004; 6:309-314.

Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR Jr, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP.  Differential gene expression in ovarian carcinoma: Identification of potential biomarkers.  Am J Pathol 2004; 165:397-414.

Skubitz KM, Skubitz AP.  Characterization of sarcomas by means of gene expression.  J Lab Clin Med 2004; 144:78-91.

Skubitz KM, Cheng EY, Clohisy DR, Thompson RC, Skubitz AP.  Gene expression in giant-cell tumors.  J Lab Clin Med 2004; 144:193-200.

Skubitz KM, Zimmerman W, Kammerer R, Pambuccian S, Skubitz AP. Differential gene expression identifies subgroups of renal cell carcinoma.
J Lab Clin Med. 2006; 147:250-67.